{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:53:09Z","timestamp":1791579189260,"version":"4.3.4"},"reference-count":129,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.pharmthera.2012.03.006","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T21:25:28Z","timestamp":1332883528000},"page":"44-53","source":"Crossref","is-referenced-by-count":153,"title":["Pharmacology and therapeutic potential of interferons"],"prefix":"10.1016","volume":"135","author":[{"given":"Peter M.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Badiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Alazawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2012.03.006_bb0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2036.2010.04370.x","article-title":"Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection","volume":"32","author":"Alazawi","year":"2010","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0015","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/QCO.0b013e32830fb924","article-title":"Advances in the diagnosis and treatment of hepatitis B","volume":"21","author":"Alazawi","year":"2008","journal-title":"Current Opinion in Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/287408a0","article-title":"A family of structural genes for human lymphoblastoid (leukocyte-type) interferon","volume":"287","author":"Allen","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/1042819021000055066","article-title":"Vascular events associated with alpha interferon therapy","volume":"44","author":"Al-Zahrani","year":"2003","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajh.10319","article-title":"Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies","volume":"73","author":"Anderson","year":"2003","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2133.1996.tb01521.x","article-title":"Raynaud's phenomenon and digital necrosis induced by interferon-alpha","volume":"135","author":"Bachmeyer","year":"1996","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0035","first-page":"38","article-title":"Activation of Toll-like receptor (TLR) 3 and TLR 8 lead to endothelin-1 release from pulmonary vascular smooth muscle: relevance to pulmonary hypertension","volume":"22","author":"Badiger","year":"2008","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0040","first-page":"38","article-title":"IP-10 (CXCL10) release following viral sensing by pulmonary artery cells-role of Toll like receptors","author":"Badiger","year":"2008","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0045","first-page":"3330","article-title":"Effect of interferon alpha preparations on IP10 and ET-1 release from human pulmonary artery smooth muscle cells","volume":"38","author":"Badiger","year":"2011","journal-title":"The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0050","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7326\/0003-4819-91-3-472","article-title":"Interferons: rationale for clinical trials in neoplastic disease","volume":"91","author":"Borden","year":"1979","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0055","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1001\/archinte.165.19.2206","article-title":"Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials","volume":"165","author":"Brok","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0060","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jaci.2011.01.023","article-title":"Exogenous IFN-\u03b2 has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus","volume":"127","author":"Cakebread","year":"2011","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0065","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1073\/pnas.74.8.3287","article-title":"Synthesis of human interferon by Xenopus laevis oocytes: two structural genes for interferons in human cells","volume":"74","author":"Cavalieri","year":"1977","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0070","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nm1462","article-title":"Role of deficient type III interferon-lambda production in asthma exacerbations","volume":"12","author":"Contoli","year":"2006","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0075","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa035115","article-title":"Expression of human herpesvirus 8 in primary pulmonary hypertension","volume":"349","author":"Cool","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/ers.11.17","article-title":"Viral infection and pulmonary hypertension: is there an association?","volume":"5","author":"Cool","year":"2011","journal-title":"Expert Review of Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0085","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clim.2004.01.008","article-title":"Interferon alpha\u2014a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity","volume":"111","author":"Devendra","year":"2004","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0095","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s10620-010-1220-7","article-title":"Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C","volume":"55","author":"Dhillon","year":"2010","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0100","doi-asserted-by":"crossref","first-page":"112S","DOI":"10.1002\/hep.510260720","article-title":"Side effects of alpha interferon in chronic hepatitis C","volume":"26","author":"Dusheiko","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0105","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/jnnp.2009.204123","article-title":"Analysis of clinical outcomes according to original treatment groups 16years after the pivotal IFNB-1b trial","volume":"81","author":"Ebers","year":"2010","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0110","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","article-title":"Type I interferon system activation and association with disease manifestations in systemic sclerosis","volume":"69","author":"Eloranta","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0115","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0120","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.gastro.2010.03.037","article-title":"Ribavirin improves early responses to peginterferon through improved interferon signaling","volume":"139","author":"Feld","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0125","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1053\/j.gastro.2011.11.028","article-title":"Hepatitis C virus infects the endothelial cells of the blood\u2013brain barrier","volume":"142","author":"Fletcher","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00042737-200604000-00005","article-title":"Central nervous system changes in hepatitis C virus infection","volume":"18","author":"Forton","year":"2006","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1046-5928(03)00055-X","article-title":"Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS)","volume":"30","author":"Foser","year":"2003","journal-title":"Protein Expression and Purification"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2893.1998.00103.x","article-title":"Are all type I human interferons equivalent?","volume":"5","author":"Foster","year":"1998","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0145","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0150","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0155","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s002770100298","article-title":"Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia","volume":"80","author":"Fruehauf","year":"2001","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0160","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1073\/pnas.89.16.7840","article-title":"The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction","volume":"89","author":"Fu","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0165","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1053\/j.gastro.2010.07.058","article-title":"Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C","volume":"139","author":"Fukuhara","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/viro.1997.8493","article-title":"Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein","volume":"230","author":"Gale","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0175","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1468-1331.2011.03410.x","article-title":"Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients","volume":"18","author":"Garcia-Montojo","year":"2011","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0180","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/00365548.2011.574150","article-title":"Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin","volume":"43","author":"Garib","year":"2011","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0185","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0190","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1089\/107999001317205240","article-title":"Structural and biologic characterization of pegylated recombinant IFN-alpha2b","volume":"21","author":"Grace","year":"2001","journal-title":"Journal of Interferon & Cytokine Research"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-2999(99)00107-7","article-title":"Interferon-alpha elevates pulmonary blood pressure in sheep\u2014the role of thromboxane cascade","volume":"370","author":"Hanaoka","year":"1999","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0200","doi-asserted-by":"crossref","first-page":"12740","DOI":"10.1128\/JVI.00987-07","article-title":"Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation","volume":"81","author":"Hebner","year":"2007","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0205","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jir.2010.0126","article-title":"Systems biology of interferon responses","volume":"31","author":"Hertzog","year":"2011","journal-title":"Journal of Interferon & Cytokine Research"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0210","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0215","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood.V82.9.2774.2774","article-title":"Exogenous tat protein activates human endothelial cells","volume":"82","author":"Hofman","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0220","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report","volume":"315","author":"Hoofnagle","year":"1986","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0225","article-title":"A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology","author":"Hu","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0230","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1073\/pnas.0609954104","article-title":"A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection","volume":"104","author":"Huang","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0235","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proceedings of the Royal Society of London\u2014Series B: Biological Sciences"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0240","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0245","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0250","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.3748\/wjg.v16.i35.4394","article-title":"Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C","volume":"16","author":"Ji","year":"2010","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0255","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-7120-3-26","article-title":"Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report","volume":"3","author":"Jochmann","year":"2005","journal-title":"Cardiovascular Ultrasound"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0260","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/bmj.306.6882.896-c","article-title":"Interstitial pneumonitis and interferon-alfa","volume":"306","author":"Kamisako","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0265","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bbrc.2005.05.198","article-title":"Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins","volume":"333","author":"Kanmogne","year":"2005","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0270","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2005.04.010","article-title":"Cell type-specific involvement of RIG-I in antiviral response","volume":"23","author":"Kato","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0275","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/gut.2010.222976","article-title":"Interferon lambdas: the next cytokine storm","volume":"60","author":"Kelly","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0280","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM199506153322402","article-title":"Long-term treatment of osteopetrosis with recombinant human interferon gamma","volume":"332","author":"Key","year":"1995","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0285","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00277-010-1114-y","article-title":"Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK\/T cell lymphoma","volume":"90","author":"Kim","year":"2011","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/sj.gene.6363984","article-title":"Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR","volume":"4","author":"Knapp","year":"2003","journal-title":"Genes and Immunity"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0295","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/262302a0","article-title":"Antiviral and cell growth inhibitory activities reside in the same glycoprotein of human fibroblast interferon","volume":"262","author":"Knight","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0300","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0305","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/107999002753675712","article-title":"Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study","volume":"22","author":"Krown","year":"2002","journal-title":"Journal of Interferon & Cytokine Research"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2012.03.006_bb0310","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1478-3231.2010.02386.x","article-title":"Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon","volume":"31","author":"Lampertico","year":"2011","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0315","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2012.03.006_bb0320","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0325","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/1352458509104593","article-title":"Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report","volume":"15","author":"Ledinek","year":"2009","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0330","doi-asserted-by":"crossref","first-page":"e11110","DOI":"10.1371\/journal.pone.0011110","article-title":"Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients","volume":"5","author":"Lehmann","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0335","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ana.410400606","article-title":"Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis","volume":"40","author":"Leppert","year":"1996","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0340","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.4049\/jimmunol.1001039","article-title":"IL-27\/IFN-\u03b3 induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages","volume":"185","author":"Li","year":"2010","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0345","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0350","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jaci.2009.03.010","article-title":"In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects","volume":"123","author":"Lopez-Souza","year":"2009","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0355","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1089\/107999000414826","article-title":"IFN-gamma enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production","volume":"20","author":"Madyastha","year":"2000","journal-title":"Journal of Interferon & Cytokine Research"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0360","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","article-title":"Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy","volume":"322","author":"Mandelli","year":"1990","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0365","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/nm.1871","article-title":"Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections","volume":"14","author":"Mandl","year":"2008","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0370","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0375","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0380","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0385","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/422993","article-title":"Long-term interferon-gamma therapy for patients with chronic granulomatous disease","volume":"39","author":"Marciano","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0390","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1164\/rccm.200601-005OC","article-title":"HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques","volume":"174","author":"Marecki","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0395","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0400","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1749-6632.2009.05241.x","article-title":"Interferon lambda as a potential new therapeutic for hepatitis C","volume":"1182","author":"Miller","year":"2009","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0405","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1113\/expphysiol.2007.038588","article-title":"Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium","volume":"93","author":"Mitchell","year":"2008","journal-title":"Experimental Physiology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0410","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.23743","article-title":"Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection","volume":"52","author":"Muir","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0415","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/j.gastro.2010.06.062","article-title":"Albinterferon Alfa-2b was not inferior to pegylated interferon-\u03b1 in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3","volume":"139","author":"Nelson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0420","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS\/MRI Study Group and the IFNB Multiple Sclerosis Study Group","volume":"43","author":"Paty","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0425","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/000331970105200105","article-title":"Primary pulmonary hypertension in HIV patients: a systematic review","volume":"52","author":"Pellicelli","year":"2001","journal-title":"Angiology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0455","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2893.1995.tb00014.x","article-title":"Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C","volume":"2","author":"P\u00e9rez","year":"1995","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0430","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/gut.2007.129478","article-title":"Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C","volume":"57","author":"Persico","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0435","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0440","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0445","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0450","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/105072503322238809","article-title":"Interferon-alpha and autoimmune thyroid disease","volume":"13","author":"Prummel","year":"2003","journal-title":"Thyroid"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0460","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa030511","article-title":"A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis","volume":"350","author":"Raghu","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0465","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0485","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7326\/0003-4819-115-3-178","article-title":"Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors","volume":"115","author":"R\u00f6nnblom","year":"1991","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0470","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.725605","article-title":"Human leukocyte interferon purified to homogeneity","volume":"202","author":"Rubinstein","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0475","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1073\/pnas.76.2.640","article-title":"Human leukocyte interferon: production, purification to homogeneity, and initial characterization","volume":"76","author":"Rubinstein","year":"1979","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0480","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ana.20224","article-title":"Defining interferon beta response status in multiple sclerosis patients","volume":"56","author":"Rudick","year":"2004","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0490","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1073\/pnas.0707882105","article-title":"Interferon signaling and treatment outcome in chronic hepatitis C","volume":"105","author":"Sarasin-Filipowicz","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0495","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1089\/107999099313415","article-title":"Suppression of late asthmatic response by low-dose oral administration of interferon-beta in the guinea pig model of asthma","volume":"19","author":"Satoh","year":"1999","journal-title":"Journal of Interferon & Cytokine Research"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0500","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1874473710801020177","article-title":"Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects","volume":"1","author":"Schaefer","year":"2008","journal-title":"Current Drug Abuse Reviews"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0505","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"Schoggins","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0510","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0515","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0520","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1126\/science.1281555","article-title":"Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein","volume":"258","author":"Shuai","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0525","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/138945011794815301","article-title":"Interferon alpha for treatment of chronic myeloid leukemia","volume":"12","author":"Simonsson","year":"2011","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0530","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(03)14541-2","article-title":"Clinical importance of neutralising antibodies against interferon beta in patients with relapsing\u2013remitting multiple sclerosis","volume":"362","author":"Sorensen","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0535","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1378\/chest.100.5.1268","article-title":"Primary pulmonary hypertension in HIV infection","volume":"100","author":"Speich","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0540","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01850","article-title":"Integration of interferon-alpha\/beta signalling to p53 responses in tumour suppression and antiviral defence","volume":"424","author":"Takaoka","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0545","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coi.2008.01.002","article-title":"MDA5\/RIG-I and virus recognition","volume":"20","author":"Takeuchi","year":"2008","journal-title":"Current Opinion in Immunology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0550","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0555","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial","volume":"45","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0560","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJM199102213240801","article-title":"A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease","volume":"324","author":"The International Chronic Granulomatous Disease Cooperative Study Group","year":"1991","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0565","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0570","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/WNL.53.8.1622","article-title":"Multiple sclerosis: side effects of interferon beta therapy and their management","volume":"53","author":"Walther","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0575","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0090-1229(92)90250-R","article-title":"Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders","volume":"65","author":"Wandl","year":"1992","journal-title":"Clinical Immunology and Immunopathology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0580","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1084\/jem.20041901","article-title":"Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus","volume":"201","author":"Wark","year":"2005","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0585","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0590","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1126\/science.149.3681.310","article-title":"Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin","volume":"149","author":"Wheelock","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0595","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2190\/PM.40.2.f","article-title":"Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury","volume":"40","author":"Wilson","year":"2010","journal-title":"International Journal of Psychiatry in Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2012.03.006_bb0600","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.1097\/00005344-199800001-00097","article-title":"Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells","volume":"31","author":"Woods","year":"1998","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0605","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0026-895X(24)23187-4","article-title":"Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme","volume":"55","author":"Woods","year":"1999","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0610","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1124\/mol.64.4.923","article-title":"Role for nuclear factor-kappaB and signal transducer and activator of transcription 1\/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells","volume":"64","author":"Woods","year":"2003","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0615","doi-asserted-by":"crossref","first-page":"24297","DOI":"10.1074\/jbc.M109.032524","article-title":"Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kappaB binding and histone acetylation at specific kappaB sites","volume":"284","author":"Wort","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0620","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1165\/ajrcmb.25.1.4331","article-title":"Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling","volume":"25","author":"Wort","year":"2001","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0625","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0630","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jcb.10074","article-title":"Characterization of interferon gamma receptors on osteoclasts: effect of interferon gamma on osteoclastic superoxide generation","volume":"84","author":"Yang","year":"2002","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0635","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/0002-9343(78)90455-2","article-title":"Pulmonary vascular changes in scleroderma","volume":"64","author":"Young","year":"1978","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0640","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1073\/pnas.95.7.3851","article-title":"Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS","volume":"95","author":"Zagury","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2012.03.006_bb0645","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2010.06.066","article-title":"Albinterferon Alfa-2b was not inferior to pegylated interferon-\u03b1 in a randomized trial of patients with chronic hepatitis C virus genotype 1","volume":"139","author":"Zeuzem","year":"2010","journal-title":"Gastroenterology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812000629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812000629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T23:59:06Z","timestamp":1742774346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725812000629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0163725812000629"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2012.03.006","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}